Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding-Reference-Cited by-同舟云学术

Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT3 receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D2-receptor binding

Published:1990-06 Issue:2 Volume:101 Page:168-171
ISSN:0033-3158
Container-title:Psychopharmacology
language:en
Short-container-title:Psychopharmacology

Author:

Koulu Markku,Lappalainen Jaakko,Hietala Jarmo,Sjöholm Birgitta

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology

Link

http://link.springer.com/content/pdf/10.1007/BF02244121.pdf

Reference25 articles.

1. Bradley PB, Engel G, Feniuk W, Fozard JR, Humprey PPA, Middlemiss DN, Mylecharane EJ, Richardson BP, Saxena PR (1986) Proposals for the classification and nomenclature of functional receptors for 5-hydroxytryptamine. Neuropharmacology 25:563–576

2. Bunney BS, Grace AA (1978) Acute and chronic haloperidol treatment: comparison of effects on nigral dopaminergic cell activity. Life Sci 25:1715–1728

3. Butler A, Hill JM, Ireland SJ, Jordan CC, Tyers MB (1988) Pharmacological properties of GR38032F, a novel antagonist at 5-HT3 receptors. Br J Pharmacol 94:397–412

4. Costall B, Domeney AM, Naylor RJ, Tyers MB (1987) Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 92:881–894

5. Hagan RM, Butler A, Hill JM, Jordan CC, Ireland SJ, Tyers MB (1987) Effect of the 5-HT3 receptor antagonist, GR38032F, on responses to injection of a neurokinin agonist into the ventral tegmental area of the rat brain. Eur J Pharmacol 138:303–305

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat;Behavioural Pharmacology;2020-12-29

2. Recent advances with 5‐HT3modulators for neuropsychiatric and gastrointestinal disorders;Medicinal Research Reviews;2020-03

3. Investigational drug therapies in phase I and phase II clinical trials for alcohol use disorders;Expert Opinion on Investigational Drugs;2018-07-27

4. Tests for Anxiolytic Activity;Drug Discovery and Evaluation: Pharmacological Assays;2017

5. Tests for Anxiolytic Activity;Drug Discovery and Evaluation: Pharmacological Assays;2016